Favorable outcomes of <i>DDX41</i>-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide.

Tiong, Ing S; Stevenson, William S; Wall, Meaghan; Yap, Yan Zhuang; Seymour, John F; Kenealy, Melita; Blombery, Piers

Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide.

Tiong, Ing S; Stevenson, William S; Wall, Meaghan; Yap, Yan Zhuang; Seymour, John F; Kenealy, Melita; Blombery, Piers.

Afiliación

Tiong IS; Peter MacCallum Cancer Centre Melbourne Victoria Australia.
Stevenson WS; The Alfred Hospital Melbourne Victoria Australia.
Wall M; Monash University Melbourne Victoria Australia.
Yap YZ; Royal North Shore Hospital St Leonards New South Wales Australia.
Seymour JF; Northern Clinical School, University of Sydney Sydney New South Wales Australia.
Kenealy M; Monash University Melbourne Victoria Australia.
Blombery P; Victorian Clinical Genetics Services, Murdoch Children's Research Institute Melbourne Victoria Australia.

EJHaem ; 4(4): 1212-1215, 2023 Nov.

Article en En | MEDLINE | ID: mdl-38024610

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: EJHaem Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google